Anti-platelet and anti-thrombotic efects of a poly-ingredient formulation: In vitro and in vivo experimental evidences

Oman Medical Journal

Volumn 27, Issue 6, 2012, Pages

  Viswanatha, G L ^a   Rafiq, Mohamed ^a   Rajesh, S ^a   Sandeep Rao, K S ^a   Azeemuddin, Mohammed ^a   Anturlikar, S D ^a   Rangesh, P ^a   Patki, P S ^a  

^a Himalaya Health Care   (India)

Author keywords

Abana ; Adrenaline induced platelet aggregation; Anti platelet; Anti thrombotic; Deep venous thrombosis

Indexed keywords

ABANA; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; IN VITRO STUDY; IN VIVO STUDY; INFERIOR CAVA VEIN; MALE; NONHUMAN; OCCLUSION; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBUS; VEIN LIGATION;

EID: 84873290333     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2012.127     Document Type: Article

References (27)

1. Bernhard N, Markus M, Irina P, David VS, Sue M, David C, et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Experiment medicine 2007; 204(13):3113-3118.
2. Stoufer GA, Smyth SS. Efects of thrombin on interactions between beta3-integrins and extracellular matrix in platelets and vascular cells. Arterioscler Tromb Vasc Biol 2003 Nov;23(11):1971-1978.
3. Grenache DG, Coleman T, Semenkovich CF, Santoro SA, Zutter MM. Alpha2beta1 integrin and development of atherosclerosis in a mouse model: assessment of risk. Arterioscler Tromb Vasc Biol 2003 Nov;23(11):2104-2109.
4. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004 Jan;14(1):18-22.
5. Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit Care Med 2002 May;30 (5 Suppl):S332-S340.
6. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009 Jun;15(6):665-673.
7. Schulman S, Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun;133 (6 Suppl):257S-298S.
8. Lilienfeld DE. Decreasing mortality from pulmonary embolism in the United States, 1979-1996. Int J Epidemiol 2000 Jun;29(3):465-469.
9. Coombes R. Venous thromboembolism caused 25,000 deaths a year, say MPs. BMJ 2005 Mar;330 (7491):559.
10. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004 Jan;164 (1):17-26.
11. Agarwal BV. Trial of AbanaÆ in ischaemia heart disease and hypertension. Probe 1986;4:314-315.
12. Vidyashankar S, Godavarthi A, Varma RS, Nandakumar KS. Water-soluble compounds in the herbal preparation Abana inhibit lipid biosynthesis and enhance cholesterol efux in HepG2 cells. Can J Physiol Pharmacol 2010 Apr;88(4):456-464.
13. Dadkar VN, Tahiliani RR, Jaguste VS, Damle VB, Dhar HL. Double blind comparative trial of Abana and methyldopa for monotherapy of hypertension in Indian patients. Jpn Heart J 1990 Mar;31(2):193-199.
14. Tiwari AK, Gode JD. A comparative study of AbanaÆ and cholesramine on serum lipids and lipoproteins in hypercholesterolemic rabbits. Arogya J Health Sci 1990;16:88-95.
15. Dubey G P, Agrawal A, Srivastava VK. Regulation of cardiovascular functions with AbanaÆ. Probe 1985;1:27-33.
16. Basu D P, Joshi RL. Abana in cardiac neurosis and similar conditions. Probe 1986;2:131-134.
17. Rao R. AbanaÆ in cardiac disease and cardiac neurosis. Probe 1988;4:274-279.
18. Yajnik VH, Acharya HK. Cardiovascular response to mental and physical stress: modifcation by AbanaÆ. Probe 1992;4:299-303.
19. Won JO, Mehari E, Ji-Young P, Yi-Seong K, Suk K, Gon-Sup K, et al. Te inhibitory efect of Opuntia humifusa Raf. Ethyl acetate extract on platelet aggregation. J Med Plants Resear 2011;5(8):1418-1424.
20. Chien M W, Shu C W, Wan JC, Hsien CL, Kun TC. Antiplatelet Efect and Selective Binding to Cyclooxygenase (COX) by Molecular Docking Analysis of Flavonoids and Lignans. Int J Mol Sci 2007;8:830-841.
21. Madiha AE, Tarek AE, Samia MA. Efect of selective and non-selective cyclooxygenase inhibitors on survival, platelet function and vein wall infammation in rat model of deep vein thrombosis. Bull Alex Fac Med 2006;42:239-240.
22. Woulfe DS. Platelet G protein-coupled receptors in hemostasis and thrombosis. J Tromb Haemost 2005 Oct;3(10):2193-2200.
23. Chang CC, Lu WJ, Chiang C W, Jayakumar T, Ong ET, Hsiao G, et al. Potent antiplatelet activity of sesamol in an in vitro and in vivo model: pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase. J Nutr Biochem 2010 Dec;21(12):1214-1221.
24. Dunlop PC, Leis LA, Johnson GJ. Epinephrine correction of impaired platelet thromboxane receptor signaling. Am J Physiol Cell Physiol 2000 Dec;279(6):C1760-C1771.
25. Schwertz H, Weyrich AS. Platelet precursors display bipolar behavior. J Cell Biol 2010 Nov;191(4):699-700.
26. Gresele P, Falcinelli E, Lofredo F, Cimmino G, Corazzi T, Forte L, et al. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J 2011 Feb;32(3):316-325.
27. Eriksson EE, Karlof E, Lundmark K, Rotzius P, Hedin U, Xie X. Powerful infammatory properties of large vein endothelium in vivo. Arterioscler Tromb Vasc Biol 2005 Apr;25(4):723-728.